A single-center analysis of visual outcomes and associated factors after intravenous methylprednisolone treatment for dysthyroid optic neuropathy

Table 3 Long-term visual acuity and proptosis at 3, 6 and 12 months after IVMP^a

Parameters	Total (n = 34 orbits)
Parameters		p-value
BCVA, logMAR (mean ± SD)
Baseline	1 (0.76)
Post-treatment (3mo)	0.61 (0.62)	*< 0.001*
Post-treatment (6mo)	0.47 (0.41)	*< 0.001*
Post-treatment (12mo)	0.47 (0.43)	*< 0.001*
Difference^b	0.53 (0.47)
Proptosis (mean ± SD)
Baseline	20.07 (3.19)
Post-treatment (3mo)	18.41 (2.17)	*< 0.001*
Post-treatment (6mo)	18.38 (2.15)	*< 0.001*
Post-treatment (12mo)	19.49 (2.83)	*< 0.001*
Difference^b	0.59 (0.66)
Improvement in BCVA – no./total no.^c (%)	26/34 (76.5)
Improvement in proptosis – no./total no.^c (%)	2/34 (5.9)
Recurrences^d	0

^aAssessment of long-term visual outcomes after 3-,6-, and 12-months of IVMP treatment. Of the 57 patients, 23 were found to be unresponsive to IVMP and had undergone orbital decompression surgery and were thus excluded from the long-term analysis. BCVA, best-corrected visual acuity; logMAR, logarithm of the minimum angle of resolution. The p-value of the comparison between 3-,6-, and 12-months with baseline values is reported. Bold italicized text indicates statistical significance
^bThe mean difference between baseline and 12-months follow-up post-treatment values were calculated and reported as mean ± standard deviation
^cFavorable outcome was considered as ≥0.2 improvements in logMAR and reduction in proptosis of ≥2 mm after treatment, for visual acuity and proptosis respectively
^dRecurrences of optic neuropathy was defined as worsening of visual acuity of ≥0.2 in logMAR after a period of normalizing visual acuity or new-onset of worsening color vision, RAPD, and disc swelling

ISSN: 1471-2415